Tag: Residual pathologic disease

Home / Residual pathologic disease

Categories

Nivolumab has been approved by the FDA for resected esophageal or gastroesophageal junction cancer

August 2021: The FDA has approved Nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with fully resected oesophagus or gastroesophageal junction (GEJ) cancer who have received neoadjuvant c...
residual-pathologic-disease

We Are Online! Chat With Us!
Scan the code